Comparison of effects of Rivaroxaban and Warfarin in treatment of patients with acute non-high-risk pulmonary thromboembolism
Objective:To compare effects of Rivaroxaban and Warfarin in treatment of patients with acute non-high-risk pulmonary thromboembolism (PTE). Methods:A prospective study was conducted on 86 patients with acute non-high-risk PTE admitted to the hospital from May 2021 to March 2023. According to the random number table method,they were divided into control group and observation group,43 cases in each group. The control group was treated with Warfarin,while the observation group was treated with Rivaroxaban. The clinical efficacy,the coagulation indexes[prothrombin time (PT),activated partial thromboplastin time (APTT),platelet count]levels,right heart function indexes[right ventricular diastolic diameter (RVDD)/left ventricular diastolic diameter (LVDD),right ventricular fractional area change (RVFAC),right ventricular Tei index,pulmonary artery systolic pressure (PASP),right ventricular tricuspid annular plane systolic excursion (TAPSE)]and blood gas analysis indexes[arterial partial pressure of carbon dioxide (PaCO2),arterial partial pressure of oxygen (PaO2)]before and after the treatment,and the incidence of adverse reactions at 6 months of treatment were compared between the two groups. Results:The total effective rate of the observation group was 95.35％ (41/43),which was higher than 79.07％ (34/43) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the levels of PT,APTT in the two groups were longer than those before the treatment,those in the observation group were longer than those in the control group;and platelet count in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group;and the differences were statistically significant (P<0.05). After the treatment,the levels of RVFAC in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the TAPSE in the two groups were bigger than those before the treatment,and that in the observation group was bigger than that in the control group;the levels of RVDD/LVDD,right ventricular Tei index and PASP levels in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant (P<0.05). After the treatment,the PaCO2 levels of the two groups were lower than those before the treatment,and that of the observation group was lower than that of the control group;the PaO2 levels of the two groups were higher than those before the treatment,and that of the observation group was higher than that of the control group;and the differences were statistically significant (P<0.05). Further,the incidence of adverse reactions in the observation group was 4.65％ (2/43),which was lower than 20.93％ (9/43) in the control group,and the difference was statistically significant (P<0.05). Conclusions:Rivaroxaban in the treatment of the patients with acute non-high-risk PTE can improve the total effective rate,improve the coagulation index levels,the right heart function and blood gas analysis index levels,and reduce the incidence of adverse events. Moreover,it is superior to Warfarin treatment.
Pulmonary thromboembolismRivaroxabanWarfarinCoagulation functionRight heart functionBlood gas analysis
万方数据
维普
